152 related articles for article (PubMed ID: 33638205)
1. The foggy world(s) of p63 isoform regulation in normal cells and cancer.
Pokorná Z; Vysloužil J; Hrabal V; Vojtěšek B; Coates PJ
J Pathol; 2021 Jul; 254(4):454-473. PubMed ID: 33638205
[TBL] [Abstract][Full Text] [Related]
2. p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.
Coates PJ; Nenutil R; Holcakova J; Nekulova M; Podhorec J; Svoboda M; Vojtesek B
Virchows Arch; 2018 Mar; 472(3):351-359. PubMed ID: 29484502
[TBL] [Abstract][Full Text] [Related]
3. DNA Demethylation Switches Oncogenic ΔNp63 to Tumor Suppressive TAp63 in Squamous Cell Carcinoma.
Pokorna Z; Hrabal V; Tichy V; Vojtesek B; Coates PJ
Front Oncol; 2022; 12():924354. PubMed ID: 35912167
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide p63-Target Gene Analyses Reveal TAp63/NRF2-Dependent Oxidative Stress Responses.
Napoli M; Deshpande AA; Chakravarti D; Rajapakshe K; Gunaratne PH; Coarfa C; Flores ER
Cancer Res Commun; 2024 Feb; 4(2):264-278. PubMed ID: 38165157
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of p63 isoforms in normal tissues and neoplastic cells.
Nylander K; Vojtesek B; Nenutil R; Lindgren B; Roos G; Zhanxiang W; Sjöström B; Dahlqvist A; Coates PJ
J Pathol; 2002 Dec; 198(4):417-27. PubMed ID: 12434410
[TBL] [Abstract][Full Text] [Related]
6. Frequent alteration of p63 expression in human primary bladder carcinomas.
Park BJ; Lee SJ; Kim JI; Lee SJ; Lee CH; Chang SG; Park JH; Chi SG
Cancer Res; 2000 Jul; 60(13):3370-4. PubMed ID: 10910040
[TBL] [Abstract][Full Text] [Related]
7. A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues.
Sethi I; Romano RA; Gluck C; Smalley K; Vojtesek B; Buck MJ; Sinha S
BMC Genomics; 2015 Aug; 16():584. PubMed ID: 26251276
[TBL] [Abstract][Full Text] [Related]
8. ΔNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis.
Park S; Lee S; Kim J; Kim G; Park KH; Kim TU; Chung D; Lee H
PLoS One; 2019; 14(4):e0214867. PubMed ID: 30973901
[TBL] [Abstract][Full Text] [Related]
9. Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry.
Nekulova M; Holcakova J; Nenutil R; Stratmann R; Bouchalova P; Müller P; Mouková L; Coates PJ; Vojtesek B
Virchows Arch; 2013 Sep; 463(3):415-25. PubMed ID: 23887585
[TBL] [Abstract][Full Text] [Related]
10. TAp63 and ΔNp63 (p40) in prostate adenocarcinomas: ΔNp63 associates with a basal-like cancer stem cell population but not with metastasis.
Galoczova M; Nenutil R; Pokorna Z; Vojtesek B; Coates PJ
Virchows Arch; 2021 Apr; 478(4):627-636. PubMed ID: 33037932
[TBL] [Abstract][Full Text] [Related]
11. Overexpression and ratio disruption of ΔNp63 and TAp63 isoform equilibrium in endometrial adenocarcinoma: correlation with obesity, menopause, and grade I/II tumors.
Vakonaki E; Soulitzis N; Sifakis S; Papadogianni D; Koutroulakis D; Spandidos DA
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1271-8. PubMed ID: 22441934
[TBL] [Abstract][Full Text] [Related]
12. Hsp70 acts as a fine-switch that controls E3 ligase CHIP-mediated TAp63 and ΔNp63 ubiquitination and degradation.
Wu HH; Wang B; Armstrong SR; Abuetabh Y; Leng S; Roa WHY; Atfi A; Marchese A; Wilson B; Sergi C; Flores ER; Eisenstat DD; Leng RP
Nucleic Acids Res; 2021 Mar; 49(5):2740-2758. PubMed ID: 33619536
[TBL] [Abstract][Full Text] [Related]
13. TAp63 and DeltaNp63 in cancer and epidermal development.
Candi E; Dinsdale D; Rufini A; Salomoni P; Knight RA; Mueller M; Krammer PH; Melino G
Cell Cycle; 2007 Feb; 6(3):274-85. PubMed ID: 17264681
[TBL] [Abstract][Full Text] [Related]
14. Metabolic pathways regulated by p63.
Candi E; Smirnov A; Panatta E; Lena AM; Novelli F; Mancini M; Viticchiè G; Piro MC; Di Daniele N; Annicchiarico-Petruzzelli M; Melino G
Biochem Biophys Res Commun; 2017 Jan; 482(3):440-444. PubMed ID: 28212728
[TBL] [Abstract][Full Text] [Related]
15. ΔNp63 silencing, DNA methylation shifts, and epithelial-mesenchymal transition resulted from TAp63 genome editing in squamous cell carcinoma.
Katoh I; Tsukinoki K; Hata RI; Kurata SI
Neoplasia; 2023 Nov; 45():100938. PubMed ID: 37778252
[TBL] [Abstract][Full Text] [Related]
16. Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes.
Abbas HA; Bui NHB; Rajapakshe K; Wong J; Gunaratne P; Tsai KY; Coarfa C; Flores ER
Cancer Res; 2018 Jan; 78(2):451-462. PubMed ID: 29180475
[TBL] [Abstract][Full Text] [Related]
17. The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site.
Orzol P; Holcakova J; Nekulova M; Nenutil R; Vojtesek B; Coates PJ
Histol Histopathol; 2015 May; 30(5):503-21. PubMed ID: 25510918
[TBL] [Abstract][Full Text] [Related]
18. p63: a crucial player in epithelial stemness regulation.
Li Y; Giovannini S; Wang T; Fang J; Li P; Shao C; Wang Y; ; Shi Y; Candi E; Melino G; Bernassola F
Oncogene; 2023 Nov; 42(46):3371-3384. PubMed ID: 37848625
[TBL] [Abstract][Full Text] [Related]
19. Identifying pathways regulating the oncogenic p53 family member ΔNp63 provides therapeutic avenues for squamous cell carcinoma.
Pokorna Z; Vyslouzil J; Vojtesek B; Coates PJ
Cell Mol Biol Lett; 2022 Feb; 27(1):18. PubMed ID: 35196980
[TBL] [Abstract][Full Text] [Related]
20. ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity.
Uchida K; Ross H; Lotan T; Pignon JC; Signoretti S; Epstein JI; Illei PB
Hum Pathol; 2015 Mar; 46(3):384-9. PubMed ID: 25548110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
